TGTX - TG Therapeutics Inc

TGTX - TG Therapeutics Inc

https://www.tgtherapeutics.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - TG Therapeutics ( NASDAQ:TGTX )

Benzinga • 1 week, 4 days ago • score: 0.35

NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 - 10, ...

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 4 days ago • score: 0.38

Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET ...

Why Is TG Therapeutics Stock Surging Wednesday? - TG Therapeutics ( NASDAQ:TGTX )

Benzinga • 1 week, 4 days ago • score: 0.47

TG Therapeutics completed a $100 million repurchase, buying 3.5 million shares at $28.55 each. The board approved a new $100 million buyback plan, sending TG Therapeutics stock higher. Post-Labor Day Trading Could Trigger Major Market Moves. Here's How to Trade It TG Therapeutics Inc.

Why Is TG Therapeutics ( TGTX ) Up 4.7% Since Last Earnings Report?

Zacks Commentary • 1 week, 5 days ago • score: 0.33

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

Zacks Commentary • 1 month, 1 week ago • score: 0.33

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

Company News for Aug 5, 2025

Zacks Commentary • 1 month, 1 week ago • score: 0.12

Companies in The News Are: ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-09 (Snapshot)

TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.

52W High

$46.48

52W Low

$21.16

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.88

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

84.76

Forward P/E (<15 better)

42.92

EV/EBITDA (<8 favorable)

52.39

EV/Revenue (<3 favorable)

11.26

P/S (TTM) (<3 favorable)

11.26

P/B (<3 favorable)

18.49

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.74%

Institutions (25–75% balanced)

64.64%

Shares Outstanding

158,666,000

Float

135,140,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

454,069,000

Gross Profit (TTM)

394,849,000

EPS (TTM)

0.38

Profit Margin (>10% good)

0.13%

Operating Margin (TTM) (higher better)

0.25%

ROE (TTM) (>15% strong)

0.27%

EPS YoY (Quarterly) (>10% good)

3.25

Revenue YoY (Quarterly) (>8% good)

0.92

Momentum

Bearish momentum

Value

0.4670

Previous

0.4089

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025